Literature DB >> 21304100

Developmental differences in megakaryocytopoiesis are associated with up-regulated TPO signaling through mTOR and elevated GATA-1 levels in neonatal megakaryocytes.

Zhi-Jian Liu1, Joseph Italiano, Francisca Ferrer-Marin, Ravi Gutti, Matthew Bailey, Brandon Poterjoy, Lisa Rimsza, Martha Sola-Visner.   

Abstract

Multiple observations support the existence of developmental differences in megakaryocytopoiesis. We have previously shown that neonatal megakaryocyte (MK) progenitors are hyperproliferative and give rise to MKs smaller and of lower ploidy than adult MKs. Based on these characteristics, neonatal MKs have been considered immature. The molecular mechanisms underlying these differences are unclear, but contribute to the pathogenesis of disorders of neonatal megakaryocytopoiesis. In the present study, we demonstrate that low-ploidy neonatal MKs, contrary to traditional belief, are more mature than adult low-ploidy MKs. These mature MKs are generated at a 10-fold higher rate than adult MKs, and result from a developmental uncoupling of proliferation, polyploidization, and terminal differentiation. This pattern is associated with up-regulated thrombopoietin (TPO) signaling through mammalian target of rapamycin (mTOR) and elevated levels of full-length GATA-1 and its targets. Blocking of mTOR with rapamycin suppressed the maturation of neonatal MKs without affecting ploidy, in contrast to the synchronous inhibition of polyploidization and cytoplasmic maturation in adult MKs. We propose that these mechanisms allow fetuses/neonates to populate their rapidly expanding bone marrow and intravascular spaces while maintaining normal platelet counts, but also set the stage for disorders restricted to fetal/neonatal MK progenitors, including the Down syndrome-transient myeloproliferative disorder and the thrombocytopenia absent radius syndrome.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21304100      PMCID: PMC3087534          DOI: 10.1182/blood-2010-07-293092

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Absence of GPIbalpha is responsible for aberrant membrane development during megakaryocyte maturation: ultrastructural study using a transgenic model.

Authors:  Christel Poujol; Jerry Ware; Bernhard Nieswandt; Alan T Nurden; Paquita Nurden
Journal:  Exp Hematol       Date:  2002-04       Impact factor: 3.084

2.  Megakaryocyte polyploidization is associated with a functional gene amplification.

Authors:  Hana Raslova; Lydia Roy; Claire Vourc'h; Jean Pierre Le Couedic; Olivier Brison; Didier Metivier; Jean Feunteun; Guido Kroemer; Najet Debili; William Vainchenker
Journal:  Blood       Date:  2002-09-05       Impact factor: 22.113

3.  Expression of CD34 and platelet glycoproteins during human megakaryocytic differentiation.

Authors:  N Debili; C Issaad; J M Massé; J Guichard; A Katz; J Breton-Gorius; W Vainchenker
Journal:  Blood       Date:  1992-12-15       Impact factor: 22.113

4.  Different ploidy levels of megakaryocytes generated from peripheral or cord blood CD34+ cells are correlated with different levels of platelet release.

Authors:  Gianfranco Mattia; Francesca Vulcano; Luisa Milazzo; Alessandra Barca; Giampiero Macioce; Adele Giampaolo; H Jane Hassan
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

5.  Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis.

Authors:  Wei Tong; Harvey F Lodish
Journal:  J Exp Med       Date:  2004-08-30       Impact factor: 14.307

6.  Alternative translation initiation site usage results in two functionally distinct forms of the GATA-1 transcription factor.

Authors:  R Calligaris; S Bottardi; S Cogoi; I Apezteguia; C Santoro
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

7.  Growth of macroscopic human megakaryocyte colonies from cord blood in culture with recombinant human thrombopoietin (c-mpl ligand) and the effects of gestational age on frequency of colonies.

Authors:  H Nishihira; Y Toyoda; H Miyazaki; H Kigasawa; E Ohsaki
Journal:  Br J Haematol       Date:  1996-01       Impact factor: 6.998

8.  The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl.

Authors:  J G Drachman; J D Griffin; K Kaushansky
Journal:  J Biol Chem       Date:  1995-03-10       Impact factor: 5.157

9.  Thrombopoietin, the Mp1 ligand, is essential for full megakaryocyte development.

Authors:  K Kaushansky; V C Broudy; N Lin; M J Jorgensen; J McCarty; N Fox; D Zucker-Franklin; C Lofton-Day
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

10.  Distinct effects of thrombopoietin depending on a threshold level of activated Mpl in BaF-3 cells.

Authors:  Gaël A Millot; William Vainchenker; Dominique Duménil; Fédor Svinarchuk
Journal:  J Cell Sci       Date:  2002-06-01       Impact factor: 5.285

View more
  39 in total

1.  Two patterns of thrombopoietin signaling suggest no coupling between platelet production and thrombopoietin reactivity in thrombocytopenia-absent radii syndrome.

Authors:  Janine Fiedler; Gabriele Strauss; Martin Wannack; Silke Schwiebert; Kerstin Seidel; Katja Henning; Eva Klopocki; Markus Schmugge; Gerhard Gaedicke; Harald Schulze
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

Review 2.  Understanding platelet generation from megakaryocytes: implications for in vitro-derived platelets.

Authors:  Xiuli Sim; Mortimer Poncz; Paul Gadue; Deborah L French
Journal:  Blood       Date:  2016-01-19       Impact factor: 22.113

3.  Nfe2 is dispensable for early but required for adult thrombocyte formation and function in zebrafish.

Authors:  Megan S Rost; Ilya Shestopalov; Yang Liu; Andy H Vo; Catherine E Richter; Sylvia M Emly; Francesca G Barrett; David L Stachura; Michael Holinstat; Leonard I Zon; Jordan A Shavit
Journal:  Blood Adv       Date:  2018-12-11

4.  Neonatal expression of RNA-binding protein IGF2BP3 regulates the human fetal-adult megakaryocyte transition.

Authors:  Kamaleldin E Elagib; Chih-Huan Lu; Goar Mosoyan; Shadi Khalil; Ewelina Zasadzińska; Daniel R Foltz; Peter Balogh; Alejandro A Gru; Deborah A Fuchs; Lisa M Rimsza; Els Verhoeyen; Miriam Sansó; Robert P Fisher; Camelia Iancu-Rubin; Adam N Goldfarb
Journal:  J Clin Invest       Date:  2017-05-08       Impact factor: 14.808

5.  MicroRNA-9 promotes cell proliferation by regulating RUNX1 expression in human megakaryocyte development.

Authors:  Sanjeev Raghuwanshi; Usha Gutti; Ravinder Kandi; Ravi Kumar Gutti
Journal:  Cell Prolif       Date:  2017-11-28       Impact factor: 6.831

Review 6.  Megakaryocyte ontogeny: Clinical and molecular significance.

Authors:  Kamaleldin E Elagib; Ashton T Brock; Adam N Goldfarb
Journal:  Exp Hematol       Date:  2018-03-02       Impact factor: 3.084

7.  Megakaryoblastic leukemia: a study on novel role of clinically significant long non-coding RNA signatures in megakaryocyte development during treatment with phorbol ester.

Authors:  Swati Dahariya; Sanjeev Raghuwanshi; Anjali Sangeeth; Mahesh Malleswarapu; Ravinder Kandi; Ravi Kumar Gutti
Journal:  Cancer Immunol Immunother       Date:  2021-04-23       Impact factor: 6.968

8.  Developmental Stage-Specific Manifestations of Absent TPO/c-MPL Signalling in Newborn Mice.

Authors:  Viola Lorenz; Haley Ramsey; Zhi-Jian Liu; Joseph Italiano; Karin Hoffmeister; Sihem Bihorel; Donald Mager; Zhongbo Hu; William B Slayton; Benjamin T Kile; Martha Sola-Visner; Francisca Ferrer-Marin
Journal:  Thromb Haemost       Date:  2017-12-06       Impact factor: 5.249

Review 9.  Challenges and promises for the development of donor-independent platelet transfusions.

Authors:  Michele P Lambert; Spencer K Sullivan; Rudy Fuentes; Deborah L French; Mortimer Poncz
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

10.  Understanding thrombocytopenia: physiological role of microRNA in survival of neonatal megakaryocytes.

Authors:  Ravinder Kandi; Usha Gutti; Rambabu Undi; Itishri Sahu; Ravi Kumar Gutti
Journal:  J Thromb Thrombolysis       Date:  2015-10       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.